-+ 0.00%
-+ 0.00%
-+ 0.00%

Achieve Life Sciences Q2 FY26 net loss widens to $74.77 million

PUBT·08/11/2026 12:32:45
Listen to the news
Achieve Life Sciences Q2 FY26 net loss widens to $74.77 million
  • Achieve Life Sciences posted a GAAP net loss of USD 74.77 million for Q2 2026, widening from USD 12.72 million a year earlier.
  • GAAP operating expenses rose to USD 18.39 million from USD 12.56 million; the loss included a USD 48.7 million non-cash warrant liability charge.
  • Cash, cash equivalents and marketable securities climbed to USD 187.3 million at June 30, 2026, from USD 36.4 million at Dec. 31, 2025.
  • FDA issued a Complete Response Letter on cytisinicline tied to cGMP observations at a prior third-party manufacturer; no efficacy or clinical safety deficiencies were cited.
  • Finished drug product manufacturing is shifting to Adare Pharma Solutions; NDA resubmission is targeted for Q4 2026 with potential FDA approval in H1 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Achieve Life Sciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608110830PRIMZONEFULLFEED9807502) on August 11, 2026, and is solely responsible for the information contained therein.